Evaluation of Non-Reducing End Pathologic Glycosaminoglycan Detection Method for Monitoring Therapeutic Response to Enzyme Replacement Therapy in Human Mucopolysaccharidosis I

Therapeutic development and monitoring require demonstration of effects on disease phenotype. However, due to the complexity of measuring clinically-relevant effects in rare multisystem diseases, robust biomarkers are essential. For the mucopolysaccharidoses (MPS), the measurement of glycosaminoglyc...

Full description

Saved in:

Bibliographic Details
Published in:	Mol Genet Metab
Main Authors:	Vera, Moin U., Le, Steven Q., Victoroff, Alla, Passage, Merry B., Brown, Jillian, Crawford, Brett E., Polgreen, Lynda E., Chen, Agnes H., Dickson, Patricia I.
Format:	Artigo
Language:	Inglês
Published:	2019
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7219480/ https://ncbi.nlm.nih.gov/pubmed/31630958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymgme.2019.09.001
Tags:	Add Tag No Tags, Be the first to tag this record!

Evaluation of Non-Reducing End Pathologic Glycosaminoglycan Detection Method for Monitoring Therapeutic Response to Enzyme Replacement Therapy in Human Mucopolysaccharidosis I

Similar Items